|  |  |
| --- | --- |
|  | **Request for access to the ImpedanCELL platform**  Measuring real-time high-throughput cellular activity  **ICORE Federative Structure 4206** |

**PROJECT**

|  |  |
| --- | --- |
| Name of the project |  |
| Services | 🞏 Autonomous use  🞏 Collaboration  🞏 Delivering service  🞏 Training |
| the project's objectives  (brief description of the essential points) |  |
| Applications | Impedance measurement (xCELLigence® technology)🞏 Cell characterization ([RTCA MP](https://aceabio.com/product/rtca-dp/)) 🞏 Proliferation / cytotoxicity ([RTCA MP](https://aceabio.com/product/rtca-dp/))  🞏 Spreading ([RTCA MP](https://aceabio.com/product/rtca-dp/) ou [RTCA DP](https://aceabio.com/product/rtca-dp/))  🞏 Cellular migration / invasion ([RTCA DP](https://aceabio.com/product/rtca-dp/))  🞏 Brightfield and/or fluorescence imaging (Cellavista)  🞏 Endpoint classical cytotoxicity test (MTS, WST-1)  🞏 Virology, manipulations in BSL-2 lab ([RTCA MP](https://aceabio.com/product/rtca-dp/))  Live cell imaging system (IncuCyte® S3)  🞏 Proliferation  🞏 Cytotoxicity (caspase-3, annexin V)  🞏 Migration/Invasion  🞏 Wound healing  🞏 Clonal dilution  🞏 Spheroids  🞏 Angiogenesis  🞏 Neurite analysis  🞏 Virology, manipulations in BSL-2 lab |
| Number of conditions envisaged  (including replicates) |  |
| Expected date of beginning of the project |  |
| Expected date of return of results |  |

|  |  |
| --- | --- |
|  | **Request for access to the ImpedanCELL platform**  Measuring real-time high-throughput cellular activity  **ICORE Federative Structure 4206** |

**USER**

|  |  |
| --- | --- |
| Name of institution or research unit |  |
| Sector | 🞏 Academic  🞏 Private |
| Name / first name of the Principal Investigator |  |
| Laboratory Adress |  |
| Name / first name of the User |  |
| User status | 🞏 Students  🞏 Technicians  🞏 Engineers  🞏 Researchers |
| User Phone number |  |
| User email |  |
| Fundings |  |

Date of the request: Signature of Applicant:

This form must be sent by email to the two scientific managers of the ImpedanCELL platform: [c.denoyelle@baclesse.unicancer.fr](mailto:c.denoyelle@baclesse.unicancer.fr) and [stephane.pronost@laboratoire-labeo.fr](mailto:stephane.pronost@laboratoire-labeo.fr)